Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma

References

• Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11(4):490–501. doi:10.1007/s11684-017-0598-429170919
   PubMed Web of Science ®Google Scholar
• Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–2108. doi:10.1002/hep.2740625164003
   PubMed Web of Science ®Google Scholar
• Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi:10.1016/S2468-1253(18)30056-629599078
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68(3):977–993. doi:10.1002/hep.2988329543988
   PubMed Web of Science ®Google Scholar
• Riaz A, Lewandowski R, Salem R. Radioembolization in advanced hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1898–1901. doi:10.1200/JCO.2018.77.722729718791
   PubMed Web of Science ®Google Scholar
• Sotiropoulos GC, Machairas N, Kostakis ID, Kouraklis G. The struggle for intensive care coverage after hepatic resections: the Greek reality. Lancet. 2017;389(10067):364–365. doi:10.1016/S0140-6736(17)30151-428137689
   PubMed Web of Science ®Google Scholar
• Chen HS, Joo DJ, Shaheen M, et al. Randomized trial of spheroid reservoir bioartificial liver in porcine model of post-hepatectomy liver failure. Hepatology. 2018 [Epub ahead of print]. doi:10.1002/hep.30184
   Web of Science ®Google Scholar
• Wang W, Huang Z, Guo B, Liu S, Xiao W, Liang J. Short- and long-term outcomes of laparoscopic hepatectomy in elderly patients with hepatocellular carcinoma. J BUON. 2018;23(4):971–978. 30358201
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen B, Wu JX, et al. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res. 2018;10:3973–3981. doi:10.2147/CMAR.S17294030310318
   PubMed Web of Science ®Google Scholar
• Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153(10):e182721. doi:10.1001/jamasurg.2018.272130073257
   PubMed Web of Science ®Google Scholar
• Lo GH. The use of steroid for transcatheter arterial chemoembolization: to relieve symptoms or to mask adverse events? Hepatology. 2018;68(3):1207. doi:10.1002/hep.30112
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Tovoli F, Pini P, Salvatore V. A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology. 2017 [Epub ahead of print] No abstract available. doi:10.1002/hep.29517
   PubMed Web of Science ®Google Scholar
• Xie H, Yu H, Tian S, et al. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? A systematic review and network meta-analysis. Oncotarget. 2017;8(59):100508–100523. doi:10.18632/oncotarget.2011929245997
   PubMedGoogle Scholar
• Feng F, Jiang Q, Jia H, et al. Which is the best combination of TACE and sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol Res. 2018;135:89–101. doi:10.1016/j.phrs.2018.06.02129959032
   PubMed Web of Science ®Google Scholar
• Wu XM, Wang JF, Ji JS, Chen MG, Song JG. Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther. 2017;10:1637–1643. doi:10.2147/OTT.S11556828352195
   PubMed Web of Science ®Google Scholar
• Yang B, Li CL, Guo WH, et al. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer. 2018;18(1):101. doi:10.1186/s12885-018-4242-829378532
   PubMedGoogle Scholar
• Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23(4):1344–1351. doi:10.1245/s10434-015-5008-z26714945
   PubMed Web of Science ®Google Scholar
• Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198(3):313–318. doi:10.1016/j.amjsurg.2008.09.02619285298
   PubMed Web of Science ®Google Scholar
• Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23:1344–1351. doi:10.1245/s10434-015-5008-z26714945
   PubMed Web of Science ®Google Scholar
• Li J, Wang Q, Lei Z, et al. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. Oncologist. 2015;20:640–647. doi:10.1634/theoncologist.2014-047025956404
   PubMed Web of Science ®Google Scholar
• Labgaa I, Demartines N, Melloul E. Surgical resection vs. transarterial chemoembolization for intermediate stage hepatocellular carcinoma (BCLC-B): an unsolved question. Hepatology. 2018 Epub ahead of print. doi:10.1002/hep.30338
   Web of Science ®Google Scholar
• Liao M, Chen P, Liao Y, et al. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection. Onco Targets Ther. 2018;11:5591–5600. doi:10.2147/OTT.S16785730237725
   PubMed Web of Science ®Google Scholar
• Calderaro J, Petitprez F, Becht E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2018:pii: S0168-8278(18)32373–0 [Epub ahead of print]. doi:10.1016/j.jhep.2018.09.003
   Web of Science ®Google Scholar
• Pinna AD, Yang T, Mazzaferro V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018;268(5):868–875. doi:10.1097/SLA.000000000000288930080736
   PubMed Web of Science ®Google Scholar
• Kudo M. Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial. Liver Cancer. 2018;7(3):225–234. doi:10.1159/00049253530319982
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505–516. doi:10.1016/j.ejrad.2008.08.00718835117
   PubMed Web of Science ®Google Scholar
• Ye JZ, Chen JZ, Li ZH, et al. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol. 2017;23(41):7415–7424. doi:10.3748/wjg.v23.i41.741529151695
   PubMed Web of Science ®Google Scholar
• Wang JH, Zhong XP, Zhang YF, et al. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis. 2017;8(9):e3043. doi:10.1038/cddis.2017.51828880268
   PubMedGoogle Scholar
• Tong Y, Li Z, Liang Y, et al. Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? A propensity score analysis. Oncotarget. 2017;8(16):26671–26678. doi:10.18632/oncotarget.1579328460456
   PubMedGoogle Scholar
• Akkiz H, Carr BI, Kuran S, et al. Macroscopic portal vein thrombosis in HCC patients. Can J Gastroenterol Hepatol. 2018;2018:3120185. doi:10.1155/2018/312018530009156
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Kido M, Takebe A, et al. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47(9):1094–1103. doi:10.1007/s00595-017-1507-928324163
   PubMed Web of Science ®Google Scholar
• Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99(12):1622–1639. doi:10.1002/bjs.891523023956
   PubMed Web of Science ®Google Scholar
• Rodrigues TFDC, Silveira B, Tavares FP, et al. Open, laparoscopic, and robotic-assisted hepatectomy in resection of liver tumors: a non-systematic review. Arq Bras Cir Dig. 2017;30(2):155–160. doi:10.1590/0102-672020170002001729257855
   PubMedGoogle Scholar
• Carr BI, Guerra V. Low alpha-fetoprotein levels are associated with improved survival in hepatocellular carcinoma patients with portal vein thrombosis. Dig Dis Sci. 2016;61(3):937–947. doi:10.1007/s10620-015-3922-326576554
   PubMed Web of Science ®Google Scholar
• Liu S, Guo L, Li H, et al. Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg Oncol. 2018;25(7):2098–2104. doi:10.1245/s10434-018-6438-129728879
   PubMed Web of Science ®Google Scholar
• Nakamura K, Beppu T, Hayashi H, et al. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. Int Surg. 2015;100(5):908–914. doi:10.9738/INTSURG-D-14-00133.126011214
   PubMed Web of Science ®Google Scholar
• Martins-Neves SR, Cleton-Jansen AM, Gomes CMF. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand? Pharmacol Res. 2018;137:193–204. doi:10.1016/j.phrs.2018.10.01130316903
   PubMed Web of Science ®Google Scholar
• Cevatemre B, Erkısa M, Aztopal N, et al. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer. Pharmacol Res. 2018;129:500–514. doi:10.1016/j.phrs.2017.11.02729197639
   PubMed Web of Science ®Google Scholar
• Hou J, Hong Z, Feng F, et al. A novel chemotherapeutic sensitivity-testing system based on collagen gel droplet embedded 3D-culture methods for hepatocellular carcinoma. BMC Cancer. 2017;17(1):729. doi:10.1186/s12885-017-3706-629117859
   PubMedGoogle Scholar
• Skoda J, Veselska R. Cancer stem cells in sarcomas: getting to the stemness core. Biochim Biophys Acta Gen Subj. 2018;1862(10):2134–2139. doi:10.1016/j.bbagen.2018.07.00630003939
   PubMed Web of Science ®Google Scholar
• Bu W, Liu Z, Jiang W, et al. Mammary precancerous stem and non-stem cells evolve into cancers of distinct subtypes. Cancer Res. 2018:pii: canres.1087.2018 [Epub ahead of print]. doi:10.1158/0008-5472.CAN-18-1087
   PubMed Web of Science ®Google Scholar
• Tsakogiannis D, Moschonas GD, Daskou M, et al. Polymorphic variability in the exon 19 of the RB1 gene and its flanking intronic sequences in HPV16-associated precancerous lesions in the Greek population. J Med Microbiol. 2018;67(11):1638–1644. doi:10.1099/jmm.0.00084330303478
   PubMed Web of Science ®Google Scholar
• Yu B, Wu K, Wang X, et al. Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7. Cell Death Dis. 2018;9(11):1082. doi:10.1038/s41419-018-1111-y30348980
   PubMedGoogle Scholar
• Voeltzel T, Flores-Violante M, Zylbersztejn F, et al. A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death Dis. 2018;9(10):1011. doi:10.1038/s41419-018-1111-y30262802
   PubMedGoogle Scholar
• Hazzah HA, Farid RM, Nasra MM, et al. A new approach for treatment of precancerous lesions with curcumin solid-lipid nanoparticle-loaded gels: in vitro and clinical evaluation. Drug Deliv. 2016;23(4):1409–1419. doi:10.3109/10717544.2015.106552426146889
   PubMed Web of Science ®Google Scholar